Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBIT (2016 - 2025)

vTv Therapeutics' EBIT history spans 12 years, with the latest figure at -$7.9 million for Q4 2025.

  • For Q4 2025, EBIT fell 61.18% year-over-year to -$7.9 million; the TTM value through Dec 2025 reached -$32.8 million, down 35.68%, while the annual FY2025 figure was -$32.8 million, 35.68% down from the prior year.
  • EBIT for Q4 2025 was -$7.9 million at vTv Therapeutics, up from -$10.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$1.6 million in Q3 2021 and bottomed at -$11.1 million in Q4 2021.
  • The 5-year median for EBIT is -$6.4 million (2022), against an average of -$6.3 million.
  • The largest YoY upside for EBIT was 43.4% in 2021 against a maximum downside of 707.05% in 2021.
  • A 5-year view of EBIT shows it stood at -$11.1 million in 2021, then surged by 42.9% to -$6.3 million in 2022, then increased by 25.79% to -$4.7 million in 2023, then decreased by 3.93% to -$4.9 million in 2024, then plummeted by 61.18% to -$7.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's EBIT are -$7.9 million (Q4 2025), -$10.7 million (Q3 2025), and -$7.7 million (Q2 2025).